1. Cahill TJ, Prendergast BD. Infective endocarditis. Lancet.2016;387(10021):882-893. doi:10.1016/S0140-6736(15)00067-7
2. Şimşek-Yavuz S, Akar AR, Aydoğdu S, et al. Diagnosis, treatment andprevention of infective endocarditis: Turkish consensus report-2019.İnfektif endokarditin tanısı, tedavisi ve önlenmesi: Ulusal uzlaşıraporu-2019. Turk Kardiyol Dern Ars. 2020;48(2):187-226. doi:10.5543/tkda.2020.89689
3. Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditisin adults: diagnosis, antimicrobial therapy, and management ofcomplications: a scientific statement for healthcare professionals fromthe American Heart Association. Circulation. 2015;132(15):1435-1486.doi:10.1161/CIR.0000000000000296
4. Ambrosioni J, Hernandez-Meneses M, Téllez A, et al. The changingepidemiology of infective endocarditis in the twenty-first century. CurrInfect Dis Rep. 2017;19(5):21. doi:10.1007/s11908-017-0574-9
5. Jensen AD, Bundgaard H, Butt JH, et al. Temporal changes in theincidence of infective endocarditis in Denmark 1997-2017: a nationwidestudy. Int J Cardiol. 2021;326:145-152. doi:10.1016/j.ijcard.2020.10.029
6. Cresti A, Chiavarelli M, Scalese M, et al. Epidemiological andmortality trends in infective endocarditis, a 17-year population-basedprospective study. Cardiovasc Diagn Ther. 2017;7(1):27-35. doi:10.21037/cdt.2016.08.09
7. Şimşek-Yavuz S, Şensoy A, Kaşıkçıoğlu H, et al. Infective endocarditisin Turkey: aetiology, clinical features, and analysis of risk factors formortality in 325 cases. Int J Infect Dis. 2015;30:106-114. doi:10.1016/j.ijid.2014.11.007
8. Mügge A, Daniel WG, Frank G, Lichtlen PR. Echocardiography ininfective endocarditis: reassessment of prognostic implications ofvegetation size determined by the transthoracic and the transesophagealapproach. J Am Coll Cardiol. 1989;14(3):631-638. doi:10.1016/0735-1097(89)90104-6
9. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis,and treatment of infective endocarditis (new version 2009): the Task Forceon the Prevention, Diagnosis, and Treatment of Infective Endocarditisof the European Society of Cardiology (ESC). Endorsed by the EuropeanSociety of Clinical Microbiology and Infectious Diseases (ESCMID)and the International Society of Chemotherapy (ISC) for Infection andCancer. Eur Heart J. 2009;30(19):2369-2413. doi:10.1093/eurheartj/ehp285
10. Tayyareci Y, Bugra Z, Meric M, Embolic events due to fungalendocarditis in the aortic valve: a case report. Turkish CardiolAssociation Res. 2007;35(6):378-381.
11. Vilacosta I, Graupner C, San Román JA, et al. Risk of embolization afterinstitution of antibiotic therapy for infective endocarditis. J Am CollCardiol. 2002;39(9):1489-1495. doi:10.1016/s0735-1097(02)01790-4
12. Kanemitsu S, Tanabe S, Ohue K, Miyagawa H, Miyake Y, Okabe M.Aortic valve destruction and pseudoaneurysm of the sinus of Valsalvaassociated with infective endocarditis. Ann Thorac Cardiovasc Surg.2010;16(2):142-144.
13. Cay S, Gürel OM, Korkmaz S. Enfektif endokarditli olgularin klinik veepidemiyolojik özellikleri [Clinical and epidemiological characteristicsof infective endocarditis]. Turk Kardiyol Dern Ars. 2009;37(3):182-186.
14. Chakraborty T, Rabinstein A, Wijdicks E. Neurologic complicationsof infective endocarditis. Handb Clin Neurol. 2021;177:125-134.doi:10.1016/B978-0-12-819814-8.00008-1